Recent discussions on X about PepGen Inc. (PEPG) have been buzzing with activity following the company's latest announcements regarding its public stock offering and insider buying. Many users are highlighting a significant investment by a director, which has sparked curiosity about the potential for future growth in the biotechnology firm's stock. The conversation also touches on the firm's innovative approach to neuromuscular disease therapies, adding a layer of intrigue to the stock's trajectory.
Additionally, posts on X reflect varied reactions to analyst updates, with some noting a raised price target and a reaffirmed 'Buy' rating from a prominent firm, while others point to intraday volatility as a concern. The mix of optimism and caution creates a dynamic dialogue, as investors weigh the promise of PepGen's clinical developments against market fluctuations. This ongoing chatter keeps the stock in sharp focus for those tracking biotech opportunities.
Note: This discussion summary was generated from an AI condensation of post data.
PepGen Inc. Insider Trading Activity
PepGen Inc. insiders have traded $PEPG stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PEPG stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 9,375,000 shares for an estimated $30,000,000
- SCIENCE ENTERPRISES PLC OXFORD purchased 200,000 shares for an estimated $640,000
- JAMES G MCARTHUR (President and CEO) has made 2 purchases buying 51,500 shares for an estimated $61,274 and 0 sales.
- PAUL STRECK (EVP, Head of R&D) purchased 8,375 shares for an estimated $10,393
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PepGen Inc. Hedge Fund Activity
We have seen 22 institutional investors add shares of PepGen Inc. stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 1,360,932 shares (-81.9%) from their portfolio in Q2 2025, for an estimated $1,510,634
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 953,626 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,058,524
- BLACKROCK, INC. removed 646,232 shares (-49.9%) from their portfolio in Q2 2025, for an estimated $717,317
- MILLENNIUM MANAGEMENT LLC added 476,180 shares (+46.1%) to their portfolio in Q2 2025, for an estimated $528,559
- STATE STREET CORP removed 250,963 shares (-78.4%) from their portfolio in Q2 2025, for an estimated $278,568
- PROSIGHT MANAGEMENT, LP added 243,980 shares (+inf%) to their portfolio in Q2 2025, for an estimated $270,817
- GEODE CAPITAL MANAGEMENT, LLC removed 182,797 shares (-47.6%) from their portfolio in Q2 2025, for an estimated $202,904
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PepGen Inc. Analyst Ratings
Wall Street analysts have issued reports on $PEPG in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 09/30/2025
- Stifel issued a "Buy" rating on 09/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/25/2025
- Guggenheim issued a "Buy" rating on 09/24/2025
To track analyst ratings and price targets for PepGen Inc., check out Quiver Quantitative's $PEPG forecast page.
PepGen Inc. Price Targets
Multiple analysts have issued price targets for $PEPG recently. We have seen 5 analysts offer price targets for $PEPG in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Laura Chico from Wedbush set a target price of $8.0 on 09/30/2025
- Paul Matteis from Stifel set a target price of $12.0 on 09/25/2025
- Ananda Ghosh from HC Wainwright & Co. set a target price of $12.0 on 09/25/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $6.0 on 09/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
